Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Journal of Cancer Research and Clinical Oncology
Erschienen in: Journal of Cancer Research and Clinical Oncology 7/2023

08.08.2022 | Research

Effects and mechanisms of GSG2 in esophageal cancer progression

verfasst von: Chong Geng, Qiang Wang, Peng-Fei Xing, Min Wang, Shao-Dong Tong, Ju-Ying Zhou

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Esophageal cancer was recognized as one of the malignant tumors with poor prognosis. Germ cell associated 2 (GSG2) has been reported to be of great significance in cell growth and tumor formation. This study aimed to investigate the biological function and molecular mechanism of GSG2 in esophageal cancer.

Methods

First, relationship between GSG2 expression and tumor characteristics in esophageal cancer patients was analyzed through immunohistochemical (IHC) staining. MTT assay, flow cytometry, cloning formation assay, wound-healing assay and Transwell assay were used to determine proliferation, apoptosis and migration of esophageal cancer cell with GSG2 knockdown in vitro. Expression of apoptosis related proteins and downstream pathway proteins after GSG2 knockdown were detected through Human Apoptosis Antibody Array and western blot analysis. The GSG2 knockdown function in vivo was explored through a xenograft tumor model.

Results

GSG2 was highly expressed in tumor tissues, which has clinical significance in predicting the malignant degree of patients with esophageal cancer. In addition, GSG2 knockdown significantly inhibited a variety of malignant biological behaviors of esophageal cancer cells, such as inhibiting proliferation, reducing colony formation, promoting apoptosis, hindering migration. The decrease of GSG2 expression in esophageal cancer cells can inhibit the xenograft tumor growth.

Conclusions

In conclusion, GSG2 was involved in esophageal cancer progression and development, which may provide an effective molecular target for the treatment of esophageal cancer in the future.
Literatur
Barsouk A, Rawla P, Hadjinicolaou AV, Aluru JS, Barsouk A (2019) Targeted therapies and immunotherapies in the treatment of esophageal cancers. Med Sci (basel, Switzerland) 7(10):100
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRefPubMed
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ (2015) He J (2016) Cancer statistics in China. CA Cancer J Clin 66(2):115–132CrossRef
Chen Y, Fu D, Zhao H, Cheng W, Xu F (2020) GSG2 (Haspin) promotes development and progression of bladder cancer through targeting KIF15 (Kinase-12). Aging 12(10):8858–8879CrossRefPubMedPubMedCentral
Dai J, Higgins JM (2005) Haspin: a mitotic histone kinase required for metaphase chromosome alignment. Cell Cycle (georgetown, Tex) 4(5):665–668CrossRefPubMed
Dai J, Sultan S, Taylor SS, Higgins JM (2005) The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment. Genes Dev 19(4):472–488CrossRefPubMedPubMedCentral
Dhiman G, Srivastava N, Goyal M, Rakha E, Lothion-Roy J, Mongan NP, Miftakhova RR, Khaiboullina SF, Rizvanov AA, Baranwal M (2019) Metadherin: a therapeutic target in multiple cancers. Front Oncol 9:349CrossRefPubMedPubMedCentral
Dizdar L, Jünemann LM, Werner TA, Verde PE, Baldus SE, Stoecklein NH, Knoefel WT, Krieg A (2018) Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer. Oncol Lett 15(3):3779–3789PubMedPubMedCentral
Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salvesen GS, Reed JC, Altieri DC (2004) An IAP-IAP complex inhibits apoptosis. J Biol Chem 279(33):34087–34090CrossRefPubMed
Drago JZ, Chandarlapaty S, Jhaveri K (2019) Targeting apoptosis: a new paradigm for the treatment of estrogen receptor-positive breast cancer. Cancer Discov 9(3):323–325CrossRefPubMed
Fatehi Hassanabad A, Chehade R, Breadner D, Raphael J (2020) Esophageal carcinoma: towards targeted therapies. Cell Oncol (dordr) 43(2):195–209CrossRefPubMed
Fulda S (2014) Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists. Oncogene 33(6):671–676CrossRefPubMed
Goldar S, Khaniani MS, Derakhshan SM, Baradaran B (2015) Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pacific J Cancer Prevention APJCP 16(6):2129–2144CrossRef
Han X, Kuang T, Ren Y, Lu Z, Liao Q, Chen W (2019) Haspin knockdown can inhibit progression and development of pancreatic cancer in vitro and vivo. Exp Cell Res 385(1):111605CrossRefPubMed
He H, Wang X, Chen J, Sun L, Sun H, Xie K (2019) High-mobility group box 1 (HMGB1) promotes angiogenesis and tumor migration by regulating hypoxia-inducible factor 1 (HIF-1α) expression via the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway in breast cancer cells. Med Sci Mon Int Med J Exper Clin Res 25:2352–2360
Hou X, Liang RB, Wei JC, Xu Y, Fu JH, Luo RZ, He JH, Zhang LJ, Lin P, Yang HX (2016) Cyclin D1 expression predicts postoperative distant metastasis and survival in resectable esophageal squamous cell carcinoma. Oncotarget 7(21):31088–31096CrossRefPubMedPubMedCentral
Huertas D, Soler M, Moreto J, Villanueva A, Martinez A, Vidal A, Charlton M, Moffat D, Patel S, McDermott J, Owen J, Brotherton D, Krige D, Cuthill S, Esteller M (2012) Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene 31(11):1408–1418CrossRefPubMed
Hughes A, Mohanasundaram D, Kireta S, Jessup CF, Drogemuller CJ, Coates PT (2013) Insulin-Like growth factor-II (IGF-II) prevents proinflammatory cytokine-induced apoptosis and significantly improves islet survival after transplantation. Transplantation 95(5):671–678CrossRefPubMed
Kashyap MK (2015) Role of insulin-like growth factor-binding proteins in the pathophysiology and tumorigenesis of gastroesophageal cancers. Tum Biol J Int Soc Oncodevelop Biol and Med 36(11):8247–8257CrossRef
Li F, Xu Y, Liu B, Singh PK, Zhao W, Jin J, Han G, Scott AW, Dong X, Huo L, Ma L, Pizzi MP, Wang Y, Li Y, Harada K, Xie M, Skinner HD, Ding S, Wang L, Krishnan SS, Ajani JA (2019) YAP1-mediated CDK6 activation confers radiation resistance in esophageal cancer—rationale for the combination of YAP1 and CDK4/6 inhibitors in esophageal cancer. Clin Cancer Res off J Am Assoc Cancer Res 25(7):2264–2277CrossRef
Li J, Xu J, Zheng Y, Gao Y, He S, Li H, Zou K, Li N, Tian J, Chen W, He J (2021) Esophageal cancer: epidemiology, risk factors and screening. Chin J Cancer Res 33(5):535–547CrossRefPubMedPubMedCentral
Morgan S, Grandis JR (2009) ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res 315(4):572–582CrossRefPubMed
Pennathur A, Gibson MK, Jobe BA, Luketich JD (2013) Oesophageal carcinoma. Lancet (london, England) 381(9864):400–412CrossRefPubMed
Qin S, Xu C, Li S, Wang X, Sun X, Wang P, Zhang B, Ren H (2015) Hyperthermia induces apoptosis by targeting Survivin in esophageal cancer. Oncol Rep 34(5):2656–2664CrossRefPubMed
Short MW, Burgers KG, Fry VT (2017) Esophageal Cancer. Am Fam Phy 95(1):22–28
Tanaka H, Yoshimura Y, Nozaki M, Yomogida K, Tsuchida J, Tosaka Y, Habu T, Nakanishi T, Okada M, Nojima H, Nishimune Y (1999) Identification and characterization of a haploid germ cell-specific nuclear protein kinase (Haspin) in spermatid nuclei and its effects on somatic cells. J Biol Chem 274(24):17049–17057CrossRefPubMed
Tokuhiro K, Miyagawa Y, Yamada S, Hirose M, Ohta H, Nishimune Y, Tanaka H (2007) The 193-base pair Gsg2 (haspin) promoter region regulates germ cell-specific expression bidirectionally and synchronously. Biol Reprod 76(3):407–414CrossRefPubMed
Wang L, Zhang Z, Yu X, Li Q, Wang Q, Chang A, Huang X, Han X, Song Y, Hu J, Pang L, Hou J, Li F (2020) SOX9/miR-203a axis drives PI3K/AKT signaling to promote esophageal cancer progression. Cancer Lett 468:14–26CrossRefPubMed
Yang S, Li X, Shen W, Hu H, Li C, Han G (2021) MicroRNA-140 represses esophageal cancer progression via targeting ZEB2 to regulate Wnt/β-catenin pathway. J Surg Res 257:267–277CrossRefPubMed
Ye Z, Zhang Z, Fang L, Tian D, Liu X (2019) Bioinformatic analysis reveals GSG2 as a potential target for breast cancer therapy. Open Life Sci 14:688–698CrossRefPubMedPubMedCentral
Yu F, Lin Y, Xu X, Liu W, Tang D, Zhou X, Wang G, Zheng Y, Xie A (2020) Knockdown of GSG2 inhibits prostate cancer progression in vitro and in vivo. Int J Oncol 57(1):139–150PubMedPubMedCentral
Zhou J, Nie W, Yuan J, Zhang Z, Mi L, Wang C, Huang R (2021) GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration. Oncol Rep 45(6):91CrossRefPubMedPubMedCentral
Metadaten
Titel
Effects and mechanisms of GSG2 in esophageal cancer progression
verfasst von
Chong Geng
Qiang Wang
Peng-Fei Xing
Min Wang
Shao-Dong Tong
Ju-Ying Zhou
Publikationsdatum
08.08.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-022-04260-2

Weitere Artikel der Ausgabe 7/2023

Journal of Cancer Research and Clinical Oncology 7/2023 Zur Ausgabe

Research

Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey

Research

Clinical, laboratory, pathological, and radiological characteristics and prognosis of patients with pulmonary salivary gland-type tumors

Research

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes

Research

IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma

Research

Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer

Research

Advantages of organ-sparing treatment approaches in metastatic kidney cancer

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise